Cholinergic Drugs: Direct/Indirect Agonists, SAR, Metabolism, and Clinical Applications (Lecture Transcript Notes)

Receptors and overall cholinergic framework

• Autonomic nervous system (ANS) drugs split into two receptor families by the type of neuron involved:

  • Cholinergic drugs acting on receptors stimulated by acetylcholine (ACh)

  • Adrenergic drugs acting on receptors stimulated by norepinephrine

• In CNS/pharmacology context here, focus is on cholinergic drugs affecting the parasympathetic system and CNS pathways related to acetylcholine

• Two main cholinergic receptor types:

  • Nicotinic receptors: ligand-gated ion channels

  • Muscarinic receptors: G-protein-coupled receptors (GPCRs)

• Summary relationships:

  • Nicotinic receptors: fast ionotropic responses at nicotinic sites

  • Muscarinic receptors: slower GPCR-mediated signals with subtypes (M1–M5) not all covered in depth here

• Visual cue for drug design: many pharmacology topics are tied to the chemical structure of acetylcholine (ACh) and how drugs mimic or interfere with native ACh

Acetylcholine: structure, properties, and receptor binding

• Acetylcholine (ACh) structure features: an ester connected to a quaternary ammonium center

  • Chemical representation: ext{Acetylcholine}=igl[ ext{CH}3igr]3 ext{N}^+- ext{CH}2- ext{CH}2- ext{O}- ext{C}(=O)- ext{CH}_3

• Key implications of the structure:

  • Quaternary ammonium (N with four substituents) is permanently charged; high polarity

  • Very little if any ability to cross the blood–brain barrier (BBB) due to permanent positive charge

  • Ester bond makes ACh highly susceptible to hydrolysis; short duration of action

• ACh as a transmitter:

  • Identified as the first neurotransmitter in CNS and parasympathetic systems

  • Synthesized in neurons and released into the synaptic cleft

• Receptor binding basics:

  • ACh binds both nicotinic and muscarinic receptors, but clinically most drugs that are effective cholinergic agents target muscarinic receptors (GPCRs)

• Practical teaching point from structure:

  • Structure helps predict pharmacokinetic and pharmacodynamic properties (lipophilicity, BBB penetration, hydrolysis rate, receptor selectivity)

• Nicotinic vs muscarinic binding context:

  • Nicotinic receptors respond to nicotine with ion-channel opening

  • Muscarinic receptors respond to muscarine-like alkaloids and other muscarinic agonists/antagonists

Biosynthesis and presynaptic handling of acetylcholine

• Presynaptic synthesis in the neuron (the “factory”):

  • ACh is made in a pathway starting with serine to ethanolamine via serine decarboxylase, yielding ethanolamine

  • Ethanolamine is converted to choline via a series of methylation steps using S-adenosylmethionine (SAM) donors:

  • Ethanolamine → choline requires three sequential methyl transfers from SAM

  • Each methyl transfer uses SAM as methyl donor and yields S-adenosylhomocysteine (SAH) as byproduct

  • Enzyme example chain (conceptual): serine decarboxylase → ethanolamine → choline via methytransferase steps

  • Choline acetyltransferase (ChAT) transfers an acetyl group from acetyl-CoA to choline to form acetylcholine

• Packaging and release:

  • Acetylcholine is packaged into vesicles in the presynaptic terminal

  • Release occurs in response to nerve impulses (exocytosis) at the synapse

• Very important structural point:

  • The acetyl donor in the final step is acetyl-CoA, not SAM

Termination of cholinergic signaling: acetylcholinesterase (AChE) mechanism

• Primary termination pathway: hydrolysis of ACh by acetylcholinesterase

• AChE enzyme features:

  • Active site contains a catalytic triad: Serine, Histidine, Glutamic acid

  • Serine acts as the nucleophile; histidine acts as a general base/acid to shuttle protons; glutamic acid stabilizes the transition state

• Mechanistic sequence (simplified):
  1) Serine-OH attacks the carbonyl carbon of ACh, forming an acetyl-enzyme intermediate and releasing choline
  2) Water, activated by histidine, attacks the acetyl-enzyme, regenerating the free enzyme and releasing acetate
  3) The choline fragment is recycled back to the presynapse

• Butyrylcholine esterase (BChE) in plasma also hydrolyzes cholinester substrates; less specific than AChE

• Therapeutic relevance:

  • Inhibitors of AChE prolong acetylcholine presence and cholinergic signaling (therapeutic for MG, glaucoma, Alzheimer's in some cases; insecticides and nerve agents exploit this mechanism)

Direct vs indirect cholinergic agonists: direct muscarinic/nicotinic activation

• Direct agonists bind directly to cholinergic receptors (muscarinic or nicotinic)

• Direct agonists examples (focus in lecture):

  • Choline esters (must have ester linkage and a positively charged amine): acetylcholine, methacholine, carbachol, bethanechol (not all listed in transcript, but contextually relevant)

  • Non-choline esters and alkaloids (not carbamates): pilocarpine (muscarinic agonist; tertiary amine; penetrates CNS more readily), cevimeline/sevimiline (cevimeline is a muscarinic agonist used for xerostomia)

• General pharmacologic effects of muscarinic agonists (parasympathomimetic):

  • Constriction of eye pupil (miosis) and accommodation, bronchoconstriction, increased glandular secretion, slowed heart rate, increased GI motility, urinary tract contraction

• Direct agonist design considerations:

  • ACh-like molecules must engage muscarinic or nicotinic receptors with appropriate steric and electronic features

  • BBB penetration considerations: quaternary ammonium reduces brain access; tertiary amines (e.g., pilocarpine) cross better

• Example receptor-binding discussion: muscarinic GPCR binding involves hydrophobic pocket interactions and specific hydrogen-bonding; ACh binding was historically thought to involve a salt bridge with Asp in the receptor but later recognized as a cation-π interaction with aromatic residues

• Clinical implications:

  • Direct agonists can be used to treat glaucoma (miotic effect) and xerostomia, among other indications; CNS penetration varies by compound

Structure-activity relationships (SAR) for muscarinic agonists: acetylcholine derivatives

• Simplified three-part model of acetylcholine that medicinal chemists analyze:

  • Part A: the acetyl (ester) group

  • Part B: the ethylene linker (two-carbon spacer)

  • Part C: the quaternary ammonium (or tertiary amine that can be protonated)

• Key SAR rules discussed:

  • The drug must possess a positively charged amine (preferably a quaternary ammonium) to maintain receptor interaction, particularly for cation-π interactions

  • The size of alkyl groups on the nitrogen should not exceed methyl; larger groups hinder fitting into the receptor binding pocket

• Eng’s rule of five (note on linker length and potency):

  • There should be no more than five atoms between the terminal nitrogen and the terminal hydrogen for optimal muscarinic potency

  • Example counting (linear): if the chain has two CH2, an O, a carbon, and a terminal hydrogen, count = 5 atoms

• Modifying the linker: can we shorten or lengthen the linker?

  • Shortening or lengthening beyond the optimal two-carbon linker reduces receptor interaction

  • Branching (beta-position methyl on the linker) can be tolerated and may alter activity

• Methacholine (beta-methyl acetylcholine):

  • Beta-methyl substitution introduces muscarinic selectivity

  • Creates a chiral center at the beta carbon; two enantiomers (R and S) are produced in racemic form

  • S-enantiomer is far more potent than R (approximately 240-fold more potent in potency assays)

  • R-enantiomer can inhibit acetylcholinesterase and extend duration, but overall racemic mixtures are often used for economic reasons because full enantiomeric separation is costly

• Carbachol (carbamate acetylcholine):

  • Replacing the acetate carbonyl with a carbamate (N–C(O)–NR2 linkage) stabilizes the molecule and slows hydrolysis by AChE

  • Carbachol is a non-selective cholinergic agonist (acts at both muscarinic and nicotinic receptors)

  • Carbachol is a carbamate analogue, less prone to gastric acid hydrolysis, and used in glaucoma; generally not for CNS action due to polarity

• Carbamates vs esters in SAR:

  • Carbamates are more resistant to enzymatic hydrolysis by AChE than esters, giving longer duration of action

  • The exchange of the carbonyl carbon to a nitrogen (carbamate) reduces electrophilicity and slows hydrolysis

• Bisanal (bisanicol): a hypothetical example combining beta-methyl substitution with a carbamate that yields muscarinic selectivity and enhanced stability (longer duration)

• Non-choline esters and alkaloids:

  • Pilocarpine (muscarinic agonist, non-choline ester; tertiary amine; crosses BBB more readily; used for open-angle glaucoma)

  • Cevidine/cevimeline (cevimeline) and related non-choline muscarinic agonists used for xerostomia

• Pharmacokinetic implications of SAR changes:

  • Beta-methyl substitution improves muscarinic selectivity but introduces stereochemistry; enantiomers differ in CNS penetration and potency

  • Carbamate substitution improves metabolic stability and can allow oral administration (narrower CNS activity depending on polarity)

• Practical exam-style takeaway:

  • Given two structures, identify muscarinic vs nicotinic selectivity based on beta-substitution and presence of carbamate vs ester

  • Identify stereochemistry (S vs R) implications for potency

Non-choline esters and alkaloids (natural product muscarinic agonists)

• Pilocarpine:

  • Natural alkaloid muscarinic agonist with tertiary amine

  • Used for open-angle glaucoma due to meiotic effect; notable for CNS penetration relative to quaternary ammonium compounds

• Sevimilin (cevimeline):

  • Non-cholinesterase inhibitor muscarinic agonist

  • Used to treat xerostomia (dry mouth) in autoimmune contexts (e.g., Sjögren's-like conditions)

  • Metabolism includes sulfur oxidation (S-oxidation) and glucuronidation, illustrating Phase II conjugation and effect on polarity

• Metabolic considerations for non-choline esters:

  • Glucuronidation adds a glucuronic acid moiety, increasing polarity and promoting renal excretion

  • Sulfur-containing moieties can undergo S-oxidation, affecting activity and clearance

  • Structural features (e.g., sulfoxide/sulfide) influence metabolic pathways and half-life

Metabolism and stability of acetylcholinesterase inhibitors and cholinergic drugs

• General principle: metabolic steps aim to increase polarity to facilitate excretion (renal or biliary)

• Example: cevimeline metabolism

  • S-oxidation and glucuronidation pathways described

  • The presence/absence of sulfur affects which metabolic routes are possible (sulfur-containing substrates can undergo oxidation)

• Stability considerations for acetylcholinesterase inhibitors (AChEIs):

  • Ester-based inhibitors tend to be rapidly hydrolyzed; more stable inhibitors use carbamate or phosphate linkages

  • Phosphate-containing inhibitors are the most stable and can be irreversible (e.g., nerve agents), whereas carbamates and esters are usually reversible under therapeutic timescales

• Storage and formulation notes (illustrative for physostigmine):

  • Physostigmine is a natural aryl carbamate that crosses the blood–brain barrier; it is used as an antidote for atropine poisoning due to CNS penetration

  • Stability challenges: oxidation to phenols can yield quinones, which are toxic; formulations include antioxidants (e.g., sodium metabisulfite or ascorbic acid) and slightly acidic pH (pH ~6) to minimize hydrolysis and oxidation

  • Relationship of pH and CNS penetration for physostigmine: tertiary amine can be neutral at certain pH levels, enabling CNS entry despite a relatively high pKa (~8.2)

  • The aromatic carbamate warhead distinguishes physostigmine and related aryl carbamates from simpler esters

Clinical uses and safety considerations

• Therapeutic roles of cholinergic agents:

  • Myasthenia gravis (MG): AChE inhibitors such as neostigmine and pyridostigmine (peripheral, poor CNS penetration due to quaternary ammonium)

  • Glaucoma: pilocarpine (muscarinic agonist) and carbachol (direct-acting cholinergic agonist) for meiotic pupil constriction

  • Xerostomia: cevimeline (non-choline muscarinic agonist) to stimulate salivary flow

  • Alzheimer's disease: AChE inhibitors (not detailed in transcript, but clinically relevant; e.g., donepezil, rivastigmine, galantamine) for CNS cholinergic enhancement

  • Insecticides and pest control: aryl- and alkyl-carbamate AChE inhibitors (e.g., carbaryl) used as household/insecticidal products; risks to humans and environmental exposure

• Toxicology and safety notes:

  • Cholinergic crisis from excess cholinergic activity (SLUDGE, meiosis, bradycardia, bronchorrhea, bronchoconstriction, sweating, muscle fasciculations, weakness)

  • Nerve agents (organophosphates, WMDs) produce irreversible AChE inhibition and require antidotes (atropine and pralidoxime) to restore AChE activity

  • Pharmacist safety considerations: route of administration, dosing, and management of potential CNS penetration; choose polar, highly ionized compounds to minimize CNS toxicity where appropriate

• Bystander/practical examples:

  • Ophthalmic diagnosis uses of AChEIs and direct agonists to test or elicit certain responses under controlled conditions; avoid systemic exposure for agents intended for local use

  • Cultural/education notes include discussions of plant alkaloids and historical uses; emphasize that many natural products can be toxins if misused (e.g., carbamate insecticides) and must be handled with care

Mechanistic and conceptual notes to aid understanding (summary and cross-links)

• Why ACh is a good drug-target starting point:

  • Direct structure–activity relationships allow prediction of receptor binding and selectivity

  • The presence of quaternary ammonium gives polarity and receptor engagement through cationic interactions

• Binding mode concepts:

  • Early models suggested a salt bridge with a putative aspartate in the receptor for acetylcholine; later refined as a cation-π interaction with aromatic residues

  • GPCRs (muscarinic receptors) involve transmembrane α-helices forming pockets in which ligands bind and trigger conformational changes

• Pharmacology design principles emphasized in lecture:

  • Balance between potency, selectivity (muscarinic vs nicotinic), and pharmacokinetic properties (absorption, distribution, CNS penetration)

  • The practical consequences of chemical modifications (beta-branching, carbamate formation, linker length) on potency, selectivity, and duration of action

• Ethical and practical implications:

  • Real-world considerations include historical and cultural references (ordeal trials) illustrating how pharmacology intersects with social beliefs and safety

  • Emphasis on safety, handling of toxicants, and the importance of proper storage and formulation to avoid degradation and toxicity

Quick reference: key equations and concepts (LaTeX-formatted)

• Acetylcholine hydrolysis (esterase mechanism):
  $ext{Acetylcholine} + ext{H}_2 ext{O} <br>ightarrow ext{Choline} + ext{Acetate} <br>ext{(catalyzed by AChE)}$

• ACh synthesis pathway (conceptual):

  • Serine → ethanolamine (serine decarboxylase)

  • Ethanolamine → choline (three sequential SAM-dependent methyl transfers)

  • Choline + Acetyl-CoA → Acetylcholine (choline acetyltransferase, ChAT)

• Fraction neutral form for a base with pKa = pKa at pH: $f</em>{ ext{neutral}}= rac{1}{1+10^{ ext{pK}<em>a- ext{pH}}}$ Example: nicotine with pKa ≈ 9.0 at pH 7.4 gives ~2–3% neutral form, enabling BBB penetration in the neutral form

• Eng's rule of five (conceptual expression):

  • There should be no more than five atoms between the terminal nitrogen (N) and the terminal hydrogen (H) in the linker for optimal muscarinic potency

• Relative hydrolysis rates (qualitative order):
  k{ ext{ester}} > k{ ext{carbonate}} > k_{ ext{phosphate}}

• Drug design takeaway (structure–function):

  • Ester-based AChE inhibitors are typically reversible with shorter duration; carbamates more stable; phosphates often irreversible

If you’d like, I can adapt these notes to a specific exam section (e.g., “direct agonists only” or “AChE inhibitors”) or add a compact one-page cheat sheet with the most test-ready facts and structures.